EIPICO continues to successfully achieve its targets in all activities .
14 August 2025
According to the consolidated financial statements announced on August 14th, covering the company's performance from 1 January to 30 June 2025:
•Net Sales: EIPICO achieved net sales of 4.610 billion EGP, with 36% growth compared to the same period last year.
•Exports: Exports raised to 1.521 billion EGP, with 27.5% growth. For years, EIPICO has maintained its position as the top
Egyptian pharmaceutical exporter, accounting for 26% of total Egyptian pharmaceutical exports to 65 countries worldwide.
•Production Volume: Production volume reached 5.043 billion EGP, with 56% growth.
•Unites Produced: The number of Unites produced was 159.63 million units, with 8% growth.
•Net Profit: EIPICO achieved a net profit after tax of 828 million EGP, with 6% growth.
According to IQVIA on the performance of pharmaceutical companies in the Egyptian market for the same period:
•The company ranked No.2 among all pharmaceutical companies operating in Egypt in the local (pharmacies and
warehouses) market, capturing a 6.4% market share.
•EIPICO alone has 8 products among the top 100 best-selling products in the local market by the number of units sold.
•The company ranked seventh in terms of sales value in the pharmacy market, with a 41% growth.